Author: PWeekly

With evidence that gout highly impacts patients with advanced CKD, through increased healthcare utilization and higher cardiovascular and bone/joint comorbidity and patients with uncontrolled gout (UCG) show to have an even...

In patients with chronic refractory gout whose serum urate (SU) was not maintained at ≤6 mg/dL, adding an additional tolerizing dose of pegloticase between the first and second biweekly administrations showed an overall response...

Serum urate (SU) responders to pegloticase experienced significant reductions in mean arterial pressure (MAP) that were independent of changes in renal function, according to prior randomized clinical trials (RCTs). To determine...

Small clinical trials have shown that concomitant immunomodulatory (IMM) drug use improves pegloticase persistence in the treatment of gout. However, real-world evidence has been lacking. Therefore, researchers evaluated...

In a large cohort of older patients with gout who started urate-lowering therapy (ULT), researchers observed a decrease in the rate in major adverse cardiovascular events (MACE) with a treat-to-target (TTT) strategy compared...

Magnetic resonance imaging (MRI) and clinical characteristics could differentiate between aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), relapsing-remitting multiple sclerosis (RR-MS), and...